Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Net Income towards Common Stockholders (2016 - 2025)

Cardiff Oncology's Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$7.2 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 38.75% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$45.9 million, down 0.93%, while the annual FY2025 figure was -$45.9 million, 0.93% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$7.2 million at Cardiff Oncology, up from -$11.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$5.2 million in Q1 2021 and bottomed at -$13.9 million in Q2 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$10.2 million (2022), against an average of -$10.0 million.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 112.13% in 2022 before it skyrocketed 38.75% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.4 million in 2021, then rose by 7.89% to -$8.7 million in 2022, then decreased by 7.35% to -$9.3 million in 2023, then fell by 26.22% to -$11.8 million in 2024, then surged by 38.75% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Net Income towards Common Stockholders are -$7.2 million (Q4 2025), -$11.3 million (Q3 2025), and -$13.9 million (Q2 2025).